Is Chemomab Therapeutics Ltd. (CMMB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.8% / 30% | 123.3% / 30% | 2.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.8% / 33% | 123.3% / 33% | 2.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.9% / 33% | 84.1% / 33% | 1.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.8% / 33% | 123.3% / 33% | 2.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.9% / 33% | 84.1% / 33% | 1.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -69.5% | |
| Return on Assets (ROA) | -38.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Total Debt | $324,000 |
| Current Ratio | 9.1 |
| Total Assets | $17M |
Price & Trading
| Last Close | $1.55 |
| 50-Day MA | $1.70 |
| 200-Day MA | $2.85 |
| Avg Volume | 83K |
| Beta | 0.5 |
|
52-Week Range
$1.35
| |
About Chemomab Therapeutics Ltd. (CMMB)
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Chemomab Therapeutics Ltd. (CMMB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Chemomab Therapeutics Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Chemomab Therapeutics Ltd.'s debt ratio?
Chemomab Therapeutics Ltd.'s debt ratio is 2.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.9%.
What are Chemomab Therapeutics Ltd.'s key financial metrics?
Chemomab Therapeutics Ltd. has a market capitalization of $11M. Return on equity stands at -69.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.